Seminars in Arthroplasty
Volume 20, Issue 4 , Pages 235-240 , December 2009

Prophylactic Modalities: Pharmacologic and Mechanical Compression

References 

  1. Sculco TP, Colwell CW, Pellegrini VD, et al. Prophylaxis against venous thromboembolic disease in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am. 2002;84:466–477
  2. Lieberman JR, Hsu WK. Prevention of venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am. 2005;87:2097–2112
  3. Westrich GH, Boettner F, Windsor RE, et al. VenaFlow plus Lovenox vs. Venaflow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty. J Arthroplasty. 2006;21(6 suppl 2):139–143
  4. Pellegrini VD, Donaldson CT, Farber DC, et al. The Mark Coventry Award: Prevention of readmission for venous thromboembolism after total knee arthroplasty. Clin Orthop Relat Res. 2006;452:21–27
  5. RD Heparin Arthroplasty Group. RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. J Bone Joint Surg Am. 1994;76:1174–1185
  6. Paiement G, Wessinger SJ, Waltman AC, et al. Low-dose warfarin versus external pneumatic compression for prophylaxis against venous thromboembolism following total hip replacement. J Arthroplasty. 1987;2:23–26
  7. Paiement GD, Beisaw N, Lotke P, et al. Advances in the prevention of venous thromboembolic disease after hip and knee operation. Orthop Rev. 1989;18:1–20
  8. Francis CW, Pellegrini VD, Marder VJ, et al. Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement. JAMA. 1992;267:2911–2915
  9. Hirsh J. Therapeutic range for the control of oral anticoagulant therapy. Arch Intern Med. 1985;145:1187–1188
  10. Hirsh J. Oral anticoagulant drugs. N Engl J Med. 1991;324:1865–1875
  11. Hirsh J, Levine MN. The optimal intensity of oral anticoagulant therapy. JAMA. 1987;258:2723–2726
  12. Hull R, Raskob G, Pineo G, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med. 1993;329:1370–1376
  13. Colwell CW, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. J Bone Joint Surg Am. 1999;81:932–940
  14. Francis CW, Pellegrini VD, Totterman S, et al. Prevention of deep-vein thrombosis after total hip arthroplasty (Comparison of warfarin and dalteparin). J Bone Joint Surg Am. 1997;79:1365–1372
  15. Arbit E, Goldberg M, Gomez-Orellana I, et al. Oral heparin: Status review. Thromb J. 2006;4:38–42
  16. Eriksson BI, Wille-Jorgenson P, Kalebo P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med. 1997;337:1329–1335
  17. Eriksson BI, Ekman S, Lindbratt S, et al. Prevention of thromboembolism with use of recombinant hirudin (Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement). J Bone Joint Surg Am. 1997;79:326–333
  18. Colwell CW, Berkowitz SD, Lieberman JR, et al. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am. 2005;87:2169–2177
  19. Cohen AT, Hirst C, Sherill B, et al. Meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery. Br J Surg. 2005;92:1335–1344
  20. Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: The BISTRO II randomized trial. J Thromb Haemost. 2005;3:103–111
  21. Bauer KA, Eriksson BI, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med. 2001;345:1305–1310
  22. Motsch J, Walther A, Bock M, et al. Update in the prevention and treatment of deep vein thrombosis and pulmonary embolism. Curr Opin Anaesthesiol. 2006;19:52–58
  23. Hirsh J, O'Donnell M, Eikelboom JW. Beyond unfractionated heparin and warfarin. Circulation. 2007;116:552–560
  24. Lassen MR, Davidson BL, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost. 2007;5:2368–2375
  25. Perzborn E, Kubitza D, Misselwitz F. Rivaroxaban: A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders. Hamostaseologie. 2007;27:282–289
  26. Laux V, Perzborn E, Kubitza D, et al. Preclinical and clinical characteristics of rivaroxaban: A novel, oral, direct factor Xa inhibitor. Semin Thromb Hemost. 2007;33:515–523
  27. Fisher WD, Eriksson BI, Bauer KA, et al. Rivaroxaban for thromboprophylaxis after orthopedic surgery: Pooled analysis of two studies. Thromb Haemost. 2007;97:931–937
  28. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358:2765–2775
  29. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776–2786
  30. Lachiewicz PF, Kelley SS, Haden LR. Two mechanical devices for prophylaxis of thromboembolism after total knee arthroplasty. J Bone Joint Surg Br. 2004;86:1137–1141
  31. Westrich GH, Sculco TP. Prophylaxis against deep venous thrombosis after total knee arthroplasty: Pneumatic plantar compression and aspirin compared with aspirin alone. J Bone Joint Surg Am. 1996;78:826–834
  32. Ryan MG, Westrich GH, Potter HG, et al. Effect of mechanical compression on the prevalence of proximal deep venous thrombosis as assessed by magnetic resonance venography. J Bone Joint Surg Am. 2002;84:1998–2004
  33. Westrich GH, Specht LM, Sharrock NE, et al. Venous haemodynamics after total knee arthroplasty: Evaluation of active dorsal to plantar flexion and several mechanical compression devices. J Bone Joint Surg Br. 1998;80:1057
  34. Westrich GH, Specht LM, Sharrock NE, et al. Pneumatic compression hemodynamics in total hip arthroplasty. Clin Orthop Relat Res. 2000;372:180–191
  35. Westrich GH, Jhon PH, Sanchez PM. Compliance in using a pneumatic compression device after total knee arthroplasty. Am J Orthop. 2003;32:135–140
  36. Merli GJ. Prevention of thrombosis with warfarin, aspirin, and mechanical methods. Clin Cornerstone. 2005;7:49–56
  37. Boscainos PJ, McLardy-Smith P, Jinnah RH. Deep vein thrombosis prophylaxis after total-knee arthroplasty. Curr Opin Orthop. 2006;17:60–67
  38. Dentali F, Ageno W, Imberti D. Retrievable vena cava filters: Clinical experience. Curr Opin Pulm Med. 2006;12:304–309
  39. Imberti D, Ageno W, Carpendo M. Retrievable vena cava filters: A review. Curr Opin Hematol. 2006;13:351–356
  40. Seshadri T, Tran H, Lau KK, et al. Ins and outs of inferior vena cava filters in patients with venous thromboembolism: The experience at Monash Medical Centre and review of the published reports. Int Med J. 2008;38:38–43
  41. Freedman KB, Brookenthal KR, Fitzgerald RH, et al. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. J Bone Joint Surg Am. 2000;82:929–938
  42. Westrich GH, Haas SB, Mosca P, et al. Meta-analysis of thromboembolic prophylaxis after total knee arthroplasty. J Bone Joint Surg Br. 2000;82:795–800
  43. González Della Valle A, Serota A, Go G, et al. Venous thromboembolism is rare with a multimodal prophylaxis protocol after total hip arthroplasty. Clin Orthop Relat Res. 2006;444:146–153
  44. Westrich GH, Rana AJ, Terry MA, et al. Thrombolembolic disease prophylaxis in patients with hip fracture. J Orthop Trauma. 2005;19:234–240
  45. Bae H, Westrich GH, Sculco TP, et al. The effect of preoperative donation of autologous blood on deep-vein thrombosis after total hip arthroplasty. J Bone Joint Surg Br. 2001;83:676–679
  46. Anders MJ, Lifeso RM, Landis M, et al. Effect of preoperative donation of autologous blood on deep-vein thrombosis following total joint arthroplasty of the hip or knee. J Bone Joint Surg Am. 1996;78:574–580
  47. Lieberman JR, Huo MM, Hanway J, et al. The prevalence of deep venous thrombosis after total hip arthroplasty with hypotensive epidural anesthesia. J Bone Joint Surg Am. 1994;76:341–348
  48. Miric A, Lombardi P, Sculco TP. Deep vein thrombosis prophylaxis: A comprehensive approach for total hip and total knee arthroplasty patient populations. Am J Orthop. 2000;4:269–274
  49. Westrich GH, Farrell C, Bono JV, et al. The incidence of venous thromboembolism after total hip arthroplasty: A specific hypotensive epidural anesthesia protocol. J Arthroplasty. 1999;14:456–463
  50. Sharrock NE, Hargett MJ, Urquhart B, et al. Factors affecting deep vein thrombosis rate following total knee arthroplasty under epidural anesthesia. J Arthroplasty. 1993;8:133–139
  51. DiGiovanni CW, Restrepo A, González Della Valle A, et al. The safety and efficacy of intraoperative heparin in total hip arthroplasty. Clin Orthop Relat Res. 2000;379:178–185

PII: S1045-4527(09)00059-5

doi: 10.1053/j.sart.2009.10.007

Seminars in Arthroplasty
Volume 20, Issue 4 , Pages 235-240 , December 2009

Article Tools